STOCK TITAN

Spero Therapeutics, Inc. - SPRO STOCK NEWS

Welcome to our dedicated news page for Spero Therapeutics (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spero Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spero Therapeutics 's position in the market.

Rhea-AI Summary
Spero Therapeutics, Inc. has appointed Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Rajavelu brings over two decades of experience in the life sciences sector and will play a key role in the company's success as they advance their pipeline and prepare for upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
management
-
Rhea-AI Summary
Spero Therapeutics, Inc. announced the grant of 65,000 restricted stock unit awards (RSUs) to a new employee under the 2019 Inducement Equity Incentive Plan. The RSUs will vest in four equal annual installments starting from November 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
Rhea-AI Summary
Spero Therapeutics approves grant of 110,000 restricted stock unit awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Spero Therapeutics to present at Cantor Fitzgerald’s Global Healthcare 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
Rhea-AI Summary
Spero Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
conferences
-
Rhea-AI Summary
Spero Therapeutics grants 83,000 RSUs to new employees under the 2019 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
Rhea-AI Summary
Spero Therapeutics, Inc. announced financial results for Q2 2023 and provided a business update. They received written agreement from the FDA for their Phase 3 PIVOT-PO trial of tebipenem HBr. The trial is expected to begin in 4Q 2023. They also provided updates on their SPR720 and SPR206 programs. Sath Shukla became the President and CEO of the company. Q2 2023 financial results showed a net loss of $11.9 million and total revenues of $2.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
-
Rhea-AI Summary
Spero Therapeutics announces FDA agreement on design of Phase 3 clinical trial for tebipenem HBr in patients with complicated urinary tract infection (cUTI)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.79%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Spero Therapeutics, Inc.

Nasdaq:SPRO

SPRO Rankings

SPRO Stock Data

77.61M
37.43M
20.38%
26.12%
1.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About SPRO

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.